整合渐进多元统计与抗凝活性评价筛选脑心通胶囊抗凝质量标志物
该研究以脑心通胶囊为对象,采用多极性溶剂提取并结合体外凝血酶/FXa抑制活性评价,通过双变量相关、灰色关联和OPLS-DA筛选出6个潜在抗凝活性标志物,并经UHPLC-Q-TOF-MS/MS鉴定、分子对接及HPLC-ESI-MS/MS含量测定验证,表明该整合策略可高效筛选中药复方抗凝质量标志物。
要点
- 75%甲醇提取的脑心通胶囊对凝血酶和FXa抑制活性较强。
- 筛选出6个潜在抗凝标志物,其中4个抑制凝血酶、5个抑制FXa。
- 活性成分占脑心通胶囊凝血酶/FXa抑制活性较大比例。
核心结论
- 所提出的整合策略可高效筛选潜在凝血酶/FXa抑制剂,用于中药复方生物活性相关质量控制。
研究设计与样本
- 采用不同比例溶剂进行多极性提取,体外评价凝血酶/FXa抑制活性。
- 采用BCA、GCA和OPLS-DA筛选与抗凝活性相关的潜在活性标志物。
- 通过UHPLC-Q-TOF-MS/MS鉴定结构,分子对接探索化合物与靶点相互作用,HPLC-ESI-MS/MS测定标志物含量。
主要发现
- 脑心通胶囊提取物对凝血酶和FXa表现出较好抑制活性,以75%甲醇(v/v)提取时尤为明显。
- 筛选出6个具有潜在抗凝活性的标志物化合物。
- 4个活性化合物具有凝血酶抑制活性:芍药苷、紫草酸、丹酚酸B和Z-藁本内酯。
- 5个活性化合物具有FXa抑制活性:3,5-二咖啡酰奎宁酸、迷迭香酸、紫草酸、丹酚酸B和Z-藁本内酯。
- 这些活性化合物占脑心通胶囊凝血酶/FXa抑制活性的较大比例,分子对接显示结合能较强。
临床怎么用
- 可将筛选出的6个标志物用于脑心通胶囊抗凝活性导向的质量控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The cardiovascular and cerebrovascular diseases affect human health globally. Naoxintong capsules (NXTs), a famous Chinese Patent Medicine, has been especially applied to treat cerebral infarction and coronary heart disease in clinical practice. The anticoagulant activity of this prescription plays an important role in this course of treatment. AIM OF THE STUDY: Thrombin and factor Xa (FXa) are two key targets considering the anticoagulant activity. The purpose of this investigation is to screen the quanlity markers as key thrombin and FXa inhibitors for the anticoagulant activity oriented quality control of Chinese patent medicine. MATERIALS AND METHODS: Simple multi-polar solvent extraction processes using various proportions of solvents were conducted and their thrombin/FXa inhibitory activities were evaluated in vitro. Bivariate correlation analysis (BCA), grey correlation analysis (GCA), and orthogonal partial least squares discriminate analysis (OPLS-DA) were adopted for screening the potential active markers related to the anticoagulant activity. The chemical structures of these active compounds were identified by UHPLC-Q-TOF-MS/MS and their thrombin/FXa inhibitory activity was determined. The molecular docking technology was applied to explore the interaction between the compounds and targets. The contribution of these anticoagulant active ingredients in NXT was also investigated. Last but not the least, the contents of these markers in NXT were determined by liquid chromatography-electrospray ionization tandem triple quadrupole mass spectrometry (HPLC-ESI-MS/MS) method. RESULTS: The results showed that the NXT extract exhibited great activity against thrombin and FXa, especially extracted by 75% methanol (v/v). Six marker compounds with potential anticoagulant activity were screened out. Therein, four of the active compounds owing thrombin inhibitory activity (paeoniflorin, lithospermic acid, salvianolic acid B, Z-ligustilide) and five of the active compounds owing FXa inhibitory activity (3,5-dicaffeoylquinic acid, rosmarinic acid, lithospermic acid, salvianolic acid B and Z-ligustilide). In addition, these active compounds accounted for a large proportion of thrombin/FXa inhibitory activity of NXTs. The binding energy also showed the strong interaction formed by close connection of the compounds to the residues of targets. CONCLUSIONS: The proposed integrated stategy could be an efficient strategy to screen potential thrombin/FXa inhibitors for the bioactivity related quanlity control of Chinese patent medicine.
引用
- Du KZ, Cui Y, Chen S, et al. An integration strategy combined progressive multivariate statistics with anticoagulant activity evaluation for screening anticoagulant quality markers in Chinese patent medicine. J Ethnopharmacol. 2022. PMID: 34990765. doi:10.1016/j.jep.2021.114964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。